Jansen Tejs, Petersen Henrik, Malskaer Cecilie M, Gabel-Jensen Charlotte, Dalhoff Kim, Eriksen Thomas, Belhage Bo, Hoegberg Lotte C G
Department of Anaesthesiology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Basic Clin Pharmacol Toxicol. 2017 May;120(5):491-497. doi: 10.1111/bcpt.12704. Epub 2017 Mar 15.
Coated activated charcoal haemoperfusion (CAC-HP) is a well-known treatment modality. Case reports have revealed conflicting results about the efficacy of CAC-HP in the treatment of amitriptyline (AT) poisoning, and no randomized clinical trials have been identified in the literature. This study aimed at quantifying the efficacy of modern CAC-HP as an adjunctive treatment of AT intoxication compared with standard care alone. Fourteen female Danish landrace pigs were randomized to either standard care or standard care plus 4 hr of CAC-HP. The pigs were anaesthetized, and vital parameters were continuously recorded. Amitriptyline infusion (7.5 mg/kg) was completed in 20 min. Thirty minutes after AT infusion, activated charcoal was instilled orally in both groups. In the intervention group, CAC-HP was initiated 60 min. after AT infusion. Blood and urine samples were collected as were vital parameters at specific time intervals. The protocol was approved by the Danish Experimental Animal Expectorate and complied with the NIH guide for care and use of laboratory animals. Data were managed according to the ARRIVE guidelines. No statistical significant differences between intervention and control groups were found when analysing for differences in AT levels in plasma at any time-point. Furthermore, significant differences between the control and intervention groups in regard to vital parameters could not be found either. In our animal model, the addition of CAC-HP did not improve the clearance of AT compared with standard treatment alone. We suggest that the effect of modern CAC-HP as a treatment modality in AT-poisoned human patients may be inadequate.
包膜活性炭血液灌流(CAC-HP)是一种广为人知的治疗方式。病例报告显示,关于CAC-HP治疗阿米替林(AT)中毒的疗效存在相互矛盾的结果,且文献中未发现随机临床试验。本研究旨在量化现代CAC-HP作为AT中毒辅助治疗与单纯标准治疗相比的疗效。14只丹麦长白母猪被随机分为标准治疗组或标准治疗加4小时CAC-HP组。对猪进行麻醉,并持续记录生命体征参数。20分钟内完成阿米替林输注(7.5mg/kg)。AT输注30分钟后,两组均口服灌入活性炭。在干预组中,AT输注60分钟后开始进行CAC-HP。在特定时间间隔采集血液和尿液样本以及生命体征参数。该方案经丹麦实验动物管理局批准,并符合美国国立卫生研究院实验室动物饲养和使用指南。数据按照ARRIVE指南进行管理。在分析任何时间点血浆中AT水平的差异时,干预组和对照组之间未发现统计学上的显著差异。此外,在生命体征参数方面,对照组和干预组之间也未发现显著差异。在我们的动物模型中,与单纯标准治疗相比,添加CAC-HP并未改善AT的清除率。我们认为,现代CAC-HP作为AT中毒人类患者的一种治疗方式,其效果可能不足。